Physician profile
Alan E Oester
NPI 1750503819
$2,353.46
in general payments reported to CMS, 2019-2025
14 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2021: $251 · 2022: $114 · 2023: $201 · 2024: $1,035 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $501.49 | 2024 | |
| Amgen INC. | $422.26 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $370.68 | 2021-2025 | Hydrus Microstent, Unity, Clareon |
| Horizon Therapeutics Plc | $212.83 | 2019-2023 | Tepezza |
| Genentech USA, INC. | $140.01 | 2023 | Vabysmo |
| Carl Zeiss Meditec, INC. | $120.91 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $115.15 | 2025 | Catalys System, Tecnis Simplicity, Veritas Vision System |
| Medline Industries Lp | $108.52 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.47 | 2019 | |
| Glaukos Corporation | $100.40 | 2022-2024 | Idose |
| Abbvie INC. | $90.52 | 2024-2025 | |
| Rayner Intraocular Lenses Limited | $24.73 | 2024 | Rayone Emv, Rayone Aspheric, Omidria |
| Boston Scientific Corporation | $22.68 | 2025 | Wavewriter Alpha Prime 16 |
| Bausch & Lomb Americas INC. | $20.81 | 2024 | Envista Envy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Oester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.